An experimental drug called teplizumab delayed the onset of type 1 diabetes by a year or more in individuals at high risk of the disease, Reuters reported. According to the article, a mid-stage study included 76 participants at high risk of developing type 1 diabetes who received either 14 days of treatment with teplizumab or a placebo. Following treatment, the percentage of diabetes-free participants was twice as high in the teplizumab group (57%) than the placebo group (28%), the article reported.
 
Two abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting showed that multimorbidity, insurance status, and income may affect survival rates of patients with multiple myeloma (MM), The American Journal of Managed Care reported. According to the article, in 1 abstract, specific comorbidities had varying effects on survival rates, with patients with multisystem impairment exhibiting the lowest survival rate. In the second abstract, findings showed that insurance type and regional income were associated with MM survival rates and patients who had private insurance had longer overall survival than those insured by Medicare, the article reported. 
 
The number of US measles causes has exceeded 1000, with 1001 total cases reported as of June 5, The Hill reported. According to the article, CDC officials said that measles cases through the first 5 months of this year were the highest in 27 years and warned that the United States was at risk of losing its measles elimination status. Most of the measles cases were concentrated in New York, the article reported.